The World Health Organization (WHO) has announced the launch of a historic vaccine trial in Uganda, aimed at combating the Sudan species of the Ebola virus.
This marks the first-ever vaccine trial for this specific strain of the virus.
The trial, known as the Solidarity Against Ebola or Tokomeza Ebola, will evaluate the effectiveness of three candidate vaccines.
The vaccines, developed by the Sabin Vaccine Institute, Oxford University/Jenner Institute/Serum Institute of India, and Merck/IAVI, will be tested in a ring vaccination design, targeting contacts of recently confirmed cases.
Uganda’s Minister of Health, Dr. Jane Ruth Aceng Acero, emphasized the importance of this trial, stating that “Uganda is showing that life-saving research can be promptly organized in the midst of an outbreak.”
The WHO has been working closely with the Ugandan government and researchers to design the trial protocol, ensure regulatory and ethical processes, and train research teams.
The trial’s launch is a significant milestone in the global response to Ebola outbreaks.
The WHO has been instrumental in coordinating the effort, with the arrival of candidate vaccines in Uganda occurring in a record 79 days since the outbreak was declared.
The Ebola outbreak in Uganda has resulted in 142 confirmed cases and 55 deaths in nine districts, as of December 5.
The WHO and Ugandan authorities are hopeful that this trial will pave the way for the development of effective vaccines against the Sudan species of the Ebola virus.
